The Effect of Ultralow-Dose Transdermal Estradiol on Urinary Incontinence in Postmenopausal Women

Department of Obstetrics and Gynecology, University of California, Davis, Davis, California, United States
Obstetrics and Gynecology (Impact Factor: 5.18). 12/2005; 106(5 Pt 1):946-52. DOI: 10.1097/01.AOG.0000182576.48290.6d
Source: PubMed


To estimate the effect of 2 years of treatment with ultralow-dose transdermal estradiol (E2) on incontinence in postmenopausal women.
Ultra Low Dose Transdermal estRogen Assessment (ULTRA) was a multicenter, randomized, double-blinded, placebo-controlled trial of unopposed ultralow-dose (0.014 mg/d) transdermal E2 for prevention of osteoporosis in 417 postmenopausal women aged 60 to 80 years. Frequency of incontinence episodes was assessed at baseline and after 4 months and 2 years of treatment using a self-reported questionnaire. We used an intention-to-treat analysis to compare change in incontinence frequency, improved (decreased 2 or more episodes per week), unchanged (increased or decreased no more than 1 episode per week), or worsened (increased 2 or more episodes per week) between the E2 and placebo groups among women with and without at least weekly incontinence at baseline.
At baseline, the prevalence of at least weekly incontinence was similar between E2 and placebo groups (43%). After 2 years, there was no difference between groups in the proportions of women with incontinence at baseline whose incontinence improved, worsened, or was unchanged. The odds ratio for worsening incontinence in the E2 compared with placebo group was 1.35 (95% confidence interval 0.75-2.42. In women without incontinence at baseline, the odds of developing at least weekly incontinence after 2 years in the E2 compared with placebo group was not significant (odds ratio 1.2, 95% confidence interval 0.7-2.2).
Two years of treatment with unopposed ultralow-dose transdermal E2 did not substantially change the frequency of incontinence symptoms or alter the risk of developing at least weekly incontinence.

Download full-text


Available from: Jeanette S Brown, Oct 13, 2014
15 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in July 2008 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. Methods: An Advisory Panel of clinicians and researchers expert in the field of women_s health was enlisted to review the July 2008 NAMS position statement, evaluate new evidence through an evidence-based analysis, and reach consensus on recommendations. The Panel_s recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. Also participating in the review process were other interested organizations who then endorsed the document. Results: Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. This paper lists all these areas along with explanatory comments. Areas that vary from the 2008 position statement are noted. A suggested reading list of key references published since the last statement is also provided. Conclusions: Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable for women who initiate HT close to menopause but decreases in older women and with time since menopause in previously untreated women.
    Menopause 03/2010; 15(4 Pt 1). DOI:10.1097/gme.0b013e31817b076a · 3.36 Impact Factor
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hormone therapy (HT) is widely used for controlling menopausal symptoms. It has also been used for the management and prevention of chronic diseases such as cardiovascular disease, osteoporosis and dementia in older women. The present review set out to assess the long term clinical effects of using HT. Nineteen randomised double-blind trials (involving 41,904 women aged 26 to 91 years) compared HT (all oestrogens, with or without progestogens, administered by oral, transdermal, subcutaneous or intranasal routes) with placebo when taken for at least one year. In healthy women (11 studies), combined continuous HT significantly increased the risk of obstruction of a vein by a blood clot (venous thrombo-embolism), fatal or nonfatal heart attack (after one year's use), stroke (after three years), breast cancer, gallbladder disease and (in women over 65 years) dementia. Long-term oestrogen alone significantly increased the risk of venous thromboembolism, stroke and gallbladder disease. Among women with cardiovascular disease (six studies) long-term use of combined HT significantly increased the risk of venous thromboembolism, particularly in the first two years of use, and gallbladder disease. HT offered the benefit of a significant reduction in the risk of fracture (no greater in women at high risk of fractures) or colorectal cancer but only after four or five years' treatment with HT, while the highest risk of cardiovascular events with combined HT occurred in the first year of use.
    Cochrane database of systematic reviews (Online) 02/2005; 7(3):CD004143. DOI:10.1002/14651858.CD004143.pub2 · 6.03 Impact Factor
Show more